DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Show other versions (1)

Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing...

Full description

Bibliographic Details
Main Authors:	Wordsworth, S, Leal, J, Blair, E, Legood, R, Thomson, K, Seller, A, Taylor, J, Watkins, H
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
by: Wordsworth, S, et al.
Published: (2006)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
by: Wordsworth, S, et al.
Published: (2010)

Evaluation of Clinical Diagnostic Potential of Next Generation Sequencing using Hypertrophic Cardiomyopathy as a Model
by: Taylor, J, et al.
Published: (2010)

A fast-throughput service for Familial Hypertrophic and Dilated Cardiomyopathy using High resolution melt curve analysis on the Lightscanner
by: Thistleton, J, et al.
Published: (2007)

Expansion of a diagnostic service for hypertrophic cardiomyopathy using next generation sequencing
by: Reid, S, et al.
Published: (2011)

Linked genetic modifiers in hypertrophic cardiomyopathy
by: Ektisham, J, et al.
Published: (2004)

Oxford Molecular Genetics Laboratory Cardiomyopathy Service
by: Thistleton, J, et al.
Published: (2006)

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.
by: Blair, E, et al.
Published: (2003)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
by: Ashrafian, H, et al.
Published: (2003)

Identification of a novel mitochondrial DNA mutation in the ND1 gene in 2 patients with hypertrophic cardiomyopathy with restrictive physiology
by: Khogali, S, et al.
Published: (2001)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
by: Carballo, S, et al.
Published: (2003)

Sudden death in hypertrophic cardiomyopathy.
by: Watkins, H
Published: (2000)

Myocardial dysfunction in hypertrophic cardiomyopathy.
by: Ashrafian, H, et al.
Published: (2001)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
by: Carballo, S, et al.
Published: (2005)

Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
by: Carballo, S, et al.
Published: (2005)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
by: Hudsmith, L, et al.
Published: (2006)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
by: Blair, E, et al.
Published: (2000)

Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy
by: Waring, A, et al.
Published: (2020)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
by: Ashrafian, H, et al.
Published: (2005)

Eliciting expert opinion for economic models: an applied example.
by: Leal, J, et al.
Published: (2007)

Novel mutations in cardiac MYPBC3 cause early onset malignant hypertrophic cardiomyopathy (HCM)
by: Carballo, S, et al.
Published: (2005)

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
by: Blair, E, et al.
Published: (2001)

The genetics of hypertrophic cardiomyopathy: Teare redux.
by: Watkins, H, et al.
Published: (2008)

Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing
by: R. R. Salakhov, et al.
Published: (2021-11-01)

A novel mutation in phospholamban causes a mixed hypertrophic and dilated cardiomyopathy phenotype with autosomal dominant inheritance
by: Carballo, S, et al.
Published: (2004)

Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies.
by: Watkins, H
Published: (2003)

Functional analysis of hypertrophic cardiomyopathy missense mutations in the light meromyosin region of beta myosin heavy chain
by: Redwood, C, et al.
Published: (2003)

Identification of a novel mitochondrial NADH dehydrogenase I (MTND1) gene mutation in two patients with hypertrophic cardiomyopathy
by: Khogali, S, et al.
Published: (2001)

Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management
by: Watkins, H
Published: (2001)

Assigning a causal role to genetic variants in hypertrophic cardiomyopathy.
by: Watkins, H
Published: (2013)

Screening for hypertrophic cardiomyopathy: a cost analysis of echocardiography, cardiac magnetic resonance and genetic testing
by: Manning Warren J, et al.
Published: (2009-01-01)

The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
by: Watkins, H, et al.
Published: (2005)

Hypertrophic Cardiomyopathy
by: Asra K. Butt, et al.
Published: (2023-03-01)

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.
by: Ashrafian, H, et al.
Published: (2011)

Cardiac Steatosis Detected in Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and Aortic Stenosis
by: Suttie, J, et al.
Published: (2011)

Private mitochondrial DNA variants in danish patients with hypertrophic cardiomyopathy.
by: Christian M Hagen, et al.
Published: (2015-01-01)

Hypertrophic cardiomyopathy
by: Sarita Gore, et al.
Published: (2022-01-01)

Hypertrophic Cardiomyopathy
by: Polakit Teekakirikul, MD, et al.
Published: (2021-09-01)

Hypertrophic cardiomyopathy
by: Murillo de Oliveira Antunes, et al.
Published: (2020-04-01)

The Role of Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy
by: Lidija Mikic, et al.
Published: (2023-07-01)